Study Looks at Illness Trajectories After Revascularization in Patients With PAD
By Elana Gotkine HealthDay Reporter
MONDAY, July 22, 2024 -- For patients undergoing lower limb revascularization for peripheral artery disease (PAD), the amputation rate is higher for nonelective patients, as is the mortality rate at five years after revascularization, according to a study published in the July 23 issue of Circulation.
Qiuju Li, Ph.D., from the London School of Hygiene and Tropical Medicine, and colleagues analyzed 94,690 patients (≥50 years) undergoing limb revascularization for PAD from 2013 to 2020 to examine the illness trajectories.
The researchers found that 34.8 percent of patients had nonelective revascularization and the others had elective procedures. The amputation rate was 15.2 and 19.9 percent at one and five years, respectively, after revascularization for nonelective patients. The corresponding amputation rates were 2.7 and 5.3 percent for elective patients. Patients who were younger, had tissue loss, diabetes, greater frailty, nonelective revascularization, and more distal procedures had higher risk of major amputation. At five years after revascularization, the mortality rate was 64.3 and 33.0 percent for nonelective and elective patients, respectively. Patients were at increased risk of mortality if they underwent major amputation within six months after index revascularization.
"People with severe forms of PAD requiring urgent surgery tend to have extremely poor disease progress," Li said in a statement. "They are at high risk of limb loss and all-cause death following the initial surgery."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2024
Read this next
ASCO: Durvalumab Plus FLOT Beneficial for Resectable Gastric, GE Junction Cancer
THURSDAY, June 5, 2025 -- For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel...
Endolymphatic Sac Decompression Effective for Vertigo, Migraine
WEDNESDAY, May 28, 2025 -- For Meniere disease (MD) patients with migraine, endolymphatic sac decompression (ELSD) is effective, providing postoperative relief of vertigo and...
One-Week Radiotherapy for Breast Cancer Safe, Effective Up to 10 Years
TUESDAY, May 27, 2025 -- A five-fraction, one-week schedule of adjuvant breast radiotherapy is as safe and effective as a standard three-week schedule for patients with invasive...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.